Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Identifieur interne : 000E63 ( Ncbi/Curation ); précédent : 000E62; suivant : 000E64Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
Auteurs : Gurutz Linazasoro [Espagne]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2004.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects), Adrenergic Agents (adverse effects), Animals, Antiparkinson Agents (classification), Antiparkinson Agents (therapeutic use), Disease Models, Animal, Dopamine (metabolism), Dopamine Agents (adverse effects), Dyskinesia, Drug-Induced (etiology), Electric Stimulation Therapy (instrumentation), Globus Pallidus (surgery), Humans, Levodopa (adverse effects), Levodopa (therapeutic use), Movement Disorders (drug therapy), Movement Disorders (etiology), Movement Disorders (therapy), Neurons (metabolism), Neurons (transplantation), Neurosurgical Procedures (methods), Oxidopamine (adverse effects), Parkinson Disease (complications), Parkinson Disease (etiology), Parkinson Disease (therapy), Treatment Failure.
- MESH :
- chemical , adverse effects : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Adrenergic Agents, Dopamine Agents, Levodopa, Oxidopamine.
- chemical , classification : Antiparkinson Agents.
- chemical , metabolism : Dopamine.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Movement Disorders.
- etiology : Dyskinesia, Drug-Induced, Movement Disorders, Parkinson Disease.
- instrumentation : Electric Stimulation Therapy.
- metabolism : Neurons.
- methods : Neurosurgical Procedures.
- surgery : Globus Pallidus.
- therapy : Movement Disorders, Parkinson Disease.
- transplantation : Neurons.
- Animals, Disease Models, Animal, Humans, Treatment Failure.
Abstract
One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management. The object of these new treatments should be to provide effective symptom control throughout the course of the disease without the development of side effects such as motor and psychiatric complications. Results of several clinical trials of new treatment options reported in the past 2 years have shown negative or unsatisfactory results. Most of the drugs and surgical procedures used in these studies had been tested previously in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys as well as in the classic 6-hydroxydopamine-lesioned rat model. They raise several questions about the true reliability of animal studies, the adequacy of the working hypotheses and design of clinical trials, the validity of tools in current use to evaluate a specific effect, and the selectivity of the drugs used. All these factors may explain failure. This review focuses on pharmacological and surgical treatments tested to improve the management of patients with motor fluctuations and dyskinesias. Some of the recent trials and possible reasons for their lack of success are critically analysed. Finally, some suggestions to avoid further failures and improve results are proposed.
DOI: 10.1002/mds.20120
PubMed: 15254931
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003421
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :003421
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :003333
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000E63
Links to Exploration step
pubmed:15254931Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.</title><author><name sortKey="Linazasoro, Gurutz" sort="Linazasoro, Gurutz" uniqKey="Linazasoro G" first="Gurutz" last="Linazasoro">Gurutz Linazasoro</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Neurología y Neurocirugía funcional, Clínica Quirón, San Sebastián, Guipúzcoa, Spain. glinazasoro@terra.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Neurología y Neurocirugía funcional, Clínica Quirón, San Sebastián, Guipúzcoa</wicri:regionArea><wicri:noRegion>Guipúzcoa</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15254931</idno><idno type="pmid">15254931</idno><idno type="doi">10.1002/mds.20120</idno><idno type="wicri:Area/PubMed/Corpus">003421</idno><idno type="wicri:Area/PubMed/Curation">003421</idno><idno type="wicri:Area/PubMed/Checkpoint">003333</idno><idno type="wicri:Area/Ncbi/Merge">000E63</idno><idno type="wicri:Area/Ncbi/Curation">000E63</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.</title><author><name sortKey="Linazasoro, Gurutz" sort="Linazasoro, Gurutz" uniqKey="Linazasoro G" first="Gurutz" last="Linazasoro">Gurutz Linazasoro</name><affiliation wicri:level="1"><nlm:affiliation>Centro de Neurología y Neurocirugía funcional, Clínica Quirón, San Sebastián, Guipúzcoa, Spain. glinazasoro@terra.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Centro de Neurología y Neurocirugía funcional, Clínica Quirón, San Sebastián, Guipúzcoa</wicri:regionArea><wicri:noRegion>Guipúzcoa</wicri:noRegion></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term><term>Adrenergic Agents (adverse effects)</term><term>Animals</term><term>Antiparkinson Agents (classification)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Disease Models, Animal</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (adverse effects)</term><term>Dyskinesia, Drug-Induced (etiology)</term><term>Electric Stimulation Therapy (instrumentation)</term><term>Globus Pallidus (surgery)</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Levodopa (therapeutic use)</term><term>Movement Disorders (drug therapy)</term><term>Movement Disorders (etiology)</term><term>Movement Disorders (therapy)</term><term>Neurons (metabolism)</term><term>Neurons (transplantation)</term><term>Neurosurgical Procedures (methods)</term><term>Oxidopamine (adverse effects)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (etiology)</term><term>Parkinson Disease (therapy)</term><term>Treatment Failure</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Adrenergic Agents</term><term>Dopamine Agents</term><term>Levodopa</term><term>Oxidopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="instrumentation" xml:lang="en"><term>Electric Stimulation Therapy</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Neurosurgical Procedures</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Globus Pallidus</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Neurons</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Treatment Failure</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">One major goal of current research in Parkinson's disease (PD) is the discovery of novel agents to improve symptomatic management. The object of these new treatments should be to provide effective symptom control throughout the course of the disease without the development of side effects such as motor and psychiatric complications. Results of several clinical trials of new treatment options reported in the past 2 years have shown negative or unsatisfactory results. Most of the drugs and surgical procedures used in these studies had been tested previously in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys as well as in the classic 6-hydroxydopamine-lesioned rat model. They raise several questions about the true reliability of animal studies, the adequacy of the working hypotheses and design of clinical trials, the validity of tools in current use to evaluate a specific effect, and the selectivity of the drugs used. All these factors may explain failure. This review focuses on pharmacological and surgical treatments tested to improve the management of patients with motor fluctuations and dyskinesias. Some of the recent trials and possible reasons for their lack of success are critically analysed. Finally, some suggestions to avoid further failures and improve results are proposed.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E63 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000E63 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:15254931
|texte= Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:15254931" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |